Internet Explorer 11 (IE11) is not supported. For the best experience please open using Chrome, Firefox, Safari or MS Edge

Our team advised the providers of finance arranged by Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities for the $7.3bn offer by Royalty Pharma for Elan Corporation plc. Our advisory team on this transaction was led by corporate partner Justin McKenna, finance partner Daragh Bohan and tax partner John Gulliver.

Elan is an Irish biotechnology company listed on NYSE and the Irish Stock Exchange. Royalty Pharma made an announcement of a firm intention to make the offer on 15 April 2013.



Share this: